Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 37,500 shares at $56.33 ($2.1M) on 2025-02-05, disclosed to the SEC on 2025-02-07.
Scheduled sale ($2.1M) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $56.33 | 12,847 | $724K | 34.1% |
| 2 | $56.33 | 12,847 | $724K | 34.1% |
| 3 | $56.92 | 5,903 | $336K | 15.9% |
| 4 | $56.92 | 5,903 | $336K | 15.9% |
| Total | $56.52 avg | 37,500 | $2.1M | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |